Pressurized intraperitoneal aerosol chemotherapy (PIPAC): Occupational health and safety aspects

Annals of Surgical Oncology

Volumn 20, Issue 11, 2013, Pages 3504-3511

  Solaß, Wiebke ^a   Giger Pabst, Urs ^a   Zieren, Jürgen ^a   Reymond, Marc A ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA; DOXORUBICIN; PYROXYLIN;

AIR ANALYSIS; AIR POLLUTION; ANAPHYLAXIS; ARTICLE; BODY SURFACE; BODY WEIGHT; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CARCINOMATOUS PERITONITIS; CONGESTIVE CARDIOMYOPATHY; DANGEROUS GOODS; DRUG ABSORPTION; DRUG EXPOSURE; DRUG SAFETY; EYE IRRITATION; FILTER; HEALTH CARE PERSONNEL; HUMAN; INNER EAR DISEASE; LAMINAR AIRFLOW; LEUKOPENIA; MUCOSA INFLAMMATION; MUTATION; NEBULIZER; NEPHROTOXICITY; OCCUPATIONAL SAFETY; PRESSURIZED INTRAPERITONEAL AEROSOL CHEMOTHERAPY; RESPIRATORY TRACT INFLAMMATION; ROOM TEMPERATURE; SIMULATION; SKIN IRRITATION; SMOKE; TREATMENT DURATION;

AEROSOLS; AIR POLLUTANTS, OCCUPATIONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOXORUBICIN; HUMANS; INHALATION EXPOSURE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; PERITONEAL NEOPLASMS; PRESSURE; UNITED STATES;

EID: 84883751128     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3039-x     Document Type: Article

References (16)

1. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol. 2003;4:277-83.
2. Alberts DS, Young L, Mason N, et al. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol. 1985;12(Suppl 4):38-42.
3. Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426-32.
4. Trédan O, Galmarini CM, Patel K, et al. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441-54.
5. Solaß W, Hetzel A, Nadiradze G, et al. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc. 2012;26:1849-55.
6. Laube BL. The expanding role of aerosols in systemic drug delivery, genetherapy, and vaccination. Respir Care. 2005;50:1161-76.
7. Minchinton AI, Tannock IF. Drug penetration in solid tumors. Nat Rev Cancer. 2006;6:583-92.
8. Jacquet P, Stuart OA, Chang D, et al. Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anticancer Drugs. 1996;7:596-603.
9. Esquis P, Consolo D, Magnin G, et al. High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg. 2006;244:106-12.
10. Solass W, Herbette A, Schwarz T, et al. Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept. Surg Endosc. 2012;26:847-52.
11. Canis M, Matsuzaki S, Bourdel N, et al. Peritoneum and laparoscopic environment. Bull Cancer. 2007;94:1043-51.
12. Zytostatika im Gesundheitsdienst. Informatiuon zur sicheren Handhabung von Zytostatika. GUV-I 8533. Berlin: Deutsche Gesetzliche Unfallversicherung; 2008.
13. Wittgen BP, Kunst PW, Perkins WR, et al. Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin. J Aerosol Med. 2006;19:385-91.
14. Otterson GA, Villalona-Calero MA, Sharma S, et al. Phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res. 2007;13:1246-52.
15. Lemarie E, Vecellio L, Hureaux J, et al. Aerosolized gemcitabine in patients with carcinoma of the lung: feasibility and safety study. J Aerosol Med Pulm Drug Deliv. 2011;24:261-70.
16. Jakubowski M. Biological monitoring versus air monitoring strategies in assessing environmental-occupational exposure. J Environ Monit. 2012;14:348-52.